Febuxostat

English name: Febuxostat

Description: light green to off-white powder.

Uses: Oxidase and dehydrogenase inhibitors. Used to treat hyperuricemia (gout).

Treatment: Febuxostat is a new generation of Huangyuanling oxidase inhibitor developed by Teijin Corporation of Japan, clinically used for the treatment of hyperuritic acid (gout), the structure is completely different from the Huang Blao Ling oxidase inhibitor drug developed 40 years ago, it is a new and efficient non-original Huang Ling oxidase selective inhibitor. Yellow Ticket Ridge oxidase is a key enzyme that promotes uric acid production. Febuxostat can reduce the level of uric acid in the blood of patients with hyperuricemia gout, clinical studies have shown that this product is safe and effective, this product is metabolized through the liver and does not rely on kidney excretion, so for patients with moderate to severe liver and kidney insufficiency, there is no need to reduce the dose. The dose is 40 or 80 chamber grams once daily and is not recommended for the treatment of gout patients without hyperuricemia.

Note: Gout is a heterogeneous group of diseases that are hereditary or acquired caused by decreased uric acid excretion and precursor metabolism. Due to excessive uric acid production in the body and decreased renal clearance, uric acid accumulates in the body, resulting in the deposition of urate crystals in joints and organs. Therefore, the usual means of treatment of gout are:

Promote uric acid excretion and inhibit uric acid production, and take appropriate measures to improve related symptoms. In the last step of Yuanhai metabolism, sub-yellow drifting is generated under the action of Huangyuanling oxidoreductase (XOR), and then further generates uric acid, inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Febuxostat is the world's latest new generation of non-bleaching selective yellow ticket oxidase inhibitor, which acts highly selectively on the oxidase, reduces uric acid synthesis in the body, reduces uric acid concentration, and effectively treats ventilation diseases

In the past 30 years, Beticketharol has been the only drug used to inhibit uric acid production in the clinic, and has been widely used in clinical practice as a gold treatment for gout, and has achieved good results in the treatment of anti-gout. Compared to Bepiu Ridge, febuxostat has obvious advantages:

(1) Bevotel alcohol only has an inhibitory effect on reduced XOR, while non-busotant has a significant inhibitory effect on oxidized and reduced XOR, so its effect of reducing uric acid is more powerful and long-lasting.

(2) Since Beticketing alcohol is an analogue of Ticketing, it inevitably causes the influence of other enzyme activities involving the metabolism of Yuanling and Yuanyuan. Therefore, in the treatment of bleached harol, repeated high-dose administration is required to maintain high drug levels. This also leads to serious and even fatal adverse reactions due to drug accumulation. Non-buxostat is a non-bleached XOR inhibitor and therefore has a better safety profile.